🇺🇸 FDA
Pipeline program

VY7523

VY7523-102

Phase 2 small_molecule active

Quick answer

VY7523 for Alzheimer's Disease (AD) is a Phase 2 program (small_molecule) at Voyager Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Voyager Therapeutics
Indication
Alzheimer's Disease (AD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials